Abstract: Cancer is a group of diseases that involve abnormal cell growth. They may invade or spread to other parts of the body. Although there are many challenges in translating biomarker research into a clinical setting, many gene- and protein-based biomarkers are already in use at some stage of patient care. Nevertheless, we still need to speed up the discovery process. High-throughput technology provides the tools needed to observe differences in nucleic acids, proteins, metabolites, and other cellular molecules between individuals of a species. In the era of omics, high-throughput analysis can generate a large amount of data on the functional and/or structural changes within the specimen. This has significantly promoted the discovery of cancer biomarkers and improved our understanding of the molecular response of cancer cells. This presentation will summarize some of my research in the discovery of cancer biomarkers using high-throughput technologies (including proteomics, microarrays, and next-generation sequencing).

Keywords: Genetic alteration, high-throughput technology, next-generation sequencing, microarray, proteomics

Biography: Dr. William Cho is a Chartered Scientist, a Registered Chinese Medicine Practitioner, Guest Professor of a number of Universities and a Fellow Member of several institutes, including the Institute of Biomedical Science (UK), Hong Kong Institute of Biomedical Science and Hong Kong Society for Molecular Diagnostic Sciences. Dr Cho has published over 400 peer-reviewed papers, e.g. Lancet Oncology, Nature Communications, Journal of Extracellular Vesicles, Clinical Cancer Research, Clinical Chemistry, Annals of Oncology, Theranostics; over dozen of books including "MicroRNAs in cancer translational research", "An omics perspective on cancer research", "Supportive cancer care with Chinese medicine", and over two dozens of book chapters. His current H-index is 60 with a total citations about 10,000 times.